

CURRICULUM VITAE

NAME: Steven G. Lin, M.D.

SPECIALTY: Medical and surgical management of diseases of the retina, macula and vitreous.

ADDRESS: 36949 Cook Street
Suite 101
Palm Desert, CA 92211
(760)340-2391

340 S. Farrell Drive
Suite A-105
Palm Springs, CA 92262
(760) 327-6225

4000 14th Street
Suite 312
Riverside, CA 92501
(951) 686-1190

EMPLOYMENT STATUS:

Current: Associate, Southern California Desert Retina Consultants,
Med. Inc., Palm Springs, CA.
Inland Retina Consultants, Riverside, CA.

1996-1998: Coordinate and provide weekend coverage for private
ophthalmology practices in Houma and Thibodaux, LA.

1986-1988: Tutored Mathematics and Physics, part-time, City College of
New York.

1982-1984: Taught English at Hlaing Campus, Rangoon University, Burma.

APPOINTMENTS:

Current: Desert Regional Medical Center Staff
St. Bernardine Medical Center Staff
Loma Linda University Medical Center Staff
Riverside Community Medical Center Consulting Staff

7/1996-7/1998: Tulane University Medical Center
Instructor, Department of Ophthalmology

7/1996-7/1998: Charity Hospital in New Orleans, LA
Staff Ophthalmologist

7/1996-7/1998: Veterans Administration Medical Center
New Orleans, LA, Staff Ophthalmologist

8/1996-8/1998: Terrebonne General Hospital
Houma, LA, Courtesy Staff

8/1996-8/1998: Thibodaux Regional Medical Center
Thibodaux, LA, Courtesy Staff

EDUCATION:

1988-1992: M.D., Cum Laude, SUNY-Health Science Center, Brooklyn, NY.

1985-1988: B.E., Electrical Engineering, Summa Cum Laude, G.P.A. 3.98,
City College of New York.

1979-1981: M.A., Institute of Education, Rangoon, Burma. Linguistics and
teaching of English as a foreign language.

1976-1979: B.A., English, Institute of Education, Rangoon, Burma.

HONORS AND AWARDS:

1984: Dean's Honor List, Queensboro Community College, New York.

1985: Dean's Honor List, City College of New York.

1988: Engineering Alumni Award, City College of New York.

1989: Bolognino Scholarship, City College of New York.

POST GRADUATE TRAINING:

1996-1998: Vitreo-retinal fellowship, Tulane University Medical Center,
New Orleans, LA.

1993-1996: Ophthalmology residency, SUNY-HSC at Brooklyn, NY.

1992-1993: Internship in Medicine, Staten Island University Hospital,
Staten Island, NY.

LICENSURE AND CERTIFICATION:

Current: California State Medical License

1993:Present National Board of Medical Examiners

1993-1996: New York State Medical License, currently inactive

1996-1999: Louisiana State Medical License, currently inactive

1999:Present Board Certified, American Board of Ophthalmology

AFFILIATIONS AND MEMBERSHIPS:

1995-present: American Academy of Ophthalmology

2002-present: American Society of Retina Specialists

RESEARCH:

Sub-Investigator: FDA Phase III Safety and Efficacy Study of Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage Study. Advanced Corneal Systems, Irvine, CA.

Sub-Investigator: FDA Phase III Randomized Study, Multicenter, Double-Masked, Placebo-Controlled Parallel Group Study of Tin Ethyl Etiopurpurpin (SnET2) Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration. Miravant Technologies, Santa Barbara, CA.

Sub-Investigator: FDA Phase III Randomized Study. Reduction in the Occurrence of Center-Threatening Diabetic Macular Edema. Eli Lilly and Company, Indianapolis, Indiana.

Sub-Investigator: SCORE Study. Two Randomized Trials to Compare the Efficacy and Safety of intravitreal Injections(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion, National Eye Institute, National Institutes of Health, Department of Health and Human Services.

Sub-Investigator: A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema conducted by the Diabetic Retinopathy Clinical Research Network (DRCRnet). National Eye Institute (NEI), National Institutes of Health (NIH), Department of Health and Human Services.

Sub-Investigator: A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema conducted by the Diabetic Retinopathy Clinical Research Network (DRCRnet). National Eye Institute (NEI), National Institutes of Health (NIH), Department of Health and Human Services.

Sub-Investigator: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion – BRAVO Study.

Sub-Investigator: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus- RIDE Study.

Sub-Investigator: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion – CRUISE Study.

Sub-Investigator: An Open-Label, Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration – Regeneron 0702 Study.

Sub-Investigator: A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration – Regeneron 0605 Study.

Sub-Investigator: Randomized Trial of Lutein, Zeaxanthin and Long-Chain Omega-3 Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration – AREDS II Study.

Sub-Investigator: A Randomized, Controlled study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration – Regeneron 0508 Study.

Sub-Investigator: A Two-Year, Multicenter, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injection of AGN 211745 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration – Allergan Study.

Sub-Investigator: A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5µg/day and ASI-001B 0.2µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema – Alimera (FAME) Study.

Sub-Investigator: An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in subjects with Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) or Macular Edema secondary to Retinal Vein Occlusion (RVO) who have completed a Genentech-Sponsored Ranibizumab study.

Sub-Investigator: A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Microplasmin Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion.

Sub-Investigator: A Phase II, Double-Masked, Multicenter, Randomized Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab administered monthly or on an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-Related Macular Degeneration.

PRESENTATIONS AND PAPERS:

Poster Presentations: Retinal Breaks and Detachment after LASIK Abstract. Modified Sulcus Fixation Technique for PCIOL by Temporary Externalization of Haptics. Bilateral Neuroretinitis in Pediatric Patients.

Characteristics of Retinal Lesions after LASIK for Eyes with Documented Pre-LASIK Retinal Examination.

ARVO Poster Presentation: Chan CK, Abraham P, Nuthi ASD, Chan KM, Lin SG. Intravitreal Ranibizumab for Treatment of Vascularized Pigment Epithelial Detachment (vPED) Associated With Age-Related Macular Degeneration (AMD): a Prospective Pilot Study, Broward County Convention Center, Greater Fort Lauderdale, FL, May 2, 2010.

ASRS Poster Presentation: Chan CK, Abraham P, Nuthi ASD, Chan KM, Lin SG. A Prospective Study of Intravitreal Ranibizumab for Treating Vascularized Pigment Epithelial Detachment due to Age-related Macular Degeneration. 28th ASRS annual meeting, 2010, Vancouver, British Columbia, Canada, Vancouver Convention Center, Aug 28-Sept 1, 2010.

Retina Society Paper Presentation: Chan CK, Abraham P, Nuthi ASD, Chan KM, Lin SG. Ranibizumab for Treating Vascularized Pigment Epithelial Detachment Due to Age related Macular Degeneration: A Prospective Randomized study. Retina Society 43rd annual meeting, San Francisco, CA, Sept 25, 2010.

ARVO Paper Presentation: Chan CK, Abraham P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA, Theodore S. High versus Conventional-dose Ranibizumab for Treating Vascularized Pigment Epithelial Detachments Associated with Age-related Macular Degeneration. AMD Clinical Trials II, Grand H, Broward County Convention Center, Greater Fort Lauderdale, FL, May 2, 2011.

ASRS Paper Presentation: Chan CK, Abrahma P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA. Management of Vascularized Pigment Epithelial Detachments due to AMD with High (2.0MG) vs. Conventional-dose (0.5MG) Ranibizumab, 29th ASRS annual meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Monday, Aug 22, 2011

ASRS Poster Presentation: Chan CK, Sarraf D, Abraham P, Nuthi ASD, Lin SG, McCannel, CA. Prospective Analysis of the Incidence and Risk Factors of RPE Tears in Eyes with Fibrovascular Pigment Epithelial Detachment and AMD, 29th ASRS meeting, Sheraton Boston Hotel and Shynes Convention Center, Boston, MA, Monday, Aug 22, 2011

Retina Society Paper Presentation: Chan, CK, Abraham P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA. High (2.0MG) versus Conventional-dose (0.5MG) Ranibizumab for Managing Vascularized Pigment Epithelial Detachments Associated with Age-related Macular Degeneration. Retina Society 44th annual Rome, Italy meeting, Sept 22, 2011